GENERAL ICD- C73: Thyroid cancer Page 2 of 15 ICD- C73: Malignant neoplasm of thyroid gland Period of diagnosis % Relative survival N=7,95 9
|
|
- Anna Bishop
- 6 years ago
- Views:
Transcription
1 Munich Cancer Registry Incidence and Mortality Selection Matrix Homepage Deutsch ICD- C73: Thyroid cancer Survival Year of diagnosis Patients 953 7,13 Diseases 957 7,18 Cases evaluated 878 6,274 Creation date 8/22/217 Export date 8/16/217 Population 4.81 m BERLIN GERMANY BAVARIA MUNICH Munich Cancer Registry at Munich Cancer Center Marchioninistr. 15 Munich, Germany E-ICD--C73-Thyroid-cancersurvival.pdf
2 GENERAL ICD- C73: Thyroid cancer Page 2 of 15 ICD- C73: Malignant neoplasm of thyroid gland Period of diagnosis % Relative survival N=7, Figure 1a. Relative survival of patients with thyroid cancer by period of diagnosis. Included in the evaluation are 7,95 cases diagnosed between 1988 and 215. The survival results of the SEER program (Surveillance, Epidemiology, and End Results) of the American National Cancer Institute (NCI) are summarized as the period of diagnosis from 2 to 214, and are represented by colored diamonds in order to facilitate comparisons between MCR and SEER. The presented survival curves are derived from clinical records with valid follow-up informations, which means that death certificate cases (DCO) cases are omitted from the analysis. With this one restriction, the MCR has provided populationbased statistics since 1998, collecting data on all cancer cases in the region of southern Bavaria. Historical data of previous time periods can be heavily selected, therefore, univariate survival comparisons of the presented time periods must be carefully considered. Nonetheless, all calculable survival curves are depicted to facilitate the comparison of long time follow-up analyses of relative survival between particular cancers. Period of diagnosis n=877 n=2,296 n=3,922 obs. % rel. % obs. % rel. % obs. % rel. % Table 1b. Observed (obs.) and relative (rel.) survival of patients with thyroid cancer by period of diagnosis for period (N=7,95). Period of diagnosis n= % n=2, % 27+ n=3, % SEER n=3,61
3 GENERAL ICD- C73: Thyroid cancer Page 3 of 15 ICD- C73: Malignant neoplasm of thyroid gland Gender % Survival N=6,218 N=6218 Gender 9 8 Male n=1, % Female n=4, % Observed Expected Relative Figure 2a. Survival of patients with thyroid cancer by gender. Included in the evaluation are 6,218 cases diagnosed between 1998 and 215. Gender Male Female n=1,695 n=4,523 obs. % rel. % obs. % rel. % Table 2b. Observed (obs.) and relative (rel.) survival of patients with thyroid cancer by gender for period (N=6,218).
4 GENERAL ICD- C73: Thyroid cancer Page 4 of 15 ICD- C73: Malignant neoplasm of thyroid gland Age category % Relative survival N=7, Figure 3a. Relative survival of patients with thyroid cancer by age category. Included in the evaluation are 7,95 cases diagnosed between 1988 and 215. Age category -49 yrs 5-59 yrs 6-69 yrs 7+ yrs n=3,196 n=1,663 n=1,33 n=96 obs. % rel. % obs. % rel. % obs. % rel. % obs. % rel. % Table 3b. Observed (obs.) and relative (rel.) survival of patients with thyroid cancer by age category for period (N=7,95). Age category -49 yrs n=3, % 5-59 yrs n=1, % 6-69 yrs n=1, % 7+ yrs n= %
5 GENERAL ICD- C73: Thyroid cancer Page 5 of 15 ICD- C73: Malignant neoplasm of thyroid gland Histology % Relative survival N=7,3 1 Histology NOS n= % Follicular n= % Papillary n=5, % Medullary n=39 4.4% Anaplastic n=28 3.% NA n=65.9% Figure 4a. Relative survival of patients with thyroid cancer by histology. For 7,3 of 7,95 cases diagnosed between 1988 and 215 valid data could be obtained for this item. The grey line represents the subgroup of 65 patients with missing values regarding histology (.9 % of 7,95 patients, the percent values of all other categories are related to n=7,3). Histology NOS Follicular Papillary Medullary Anaplastic NA n=317 n=87 n=5,389 n=39 n=28 n=65 obs. % rel. % obs. % rel. % obs. % rel. % obs. % rel. % obs. % rel. % obs. % rel. % Table 4b. Observed (obs.) and relative (rel.) survival of patients with thyroid cancer by histology for period (N=7,3).
6 GENERAL ICD- C73: Thyroid cancer Page 6 of 15 ICD- C73: Malignant neoplasm of thyroid gland % Relative survival N=2, T1 n=1, % T2 n= % T3+4 n= % N n=1, % N+ n= % NX n=46 2.6% M1 n= % NA/NOS n=67 3.% Figure 4c. Relative survival of patients with thyroid cancer by. For 2,232 of 2,296 cases diagnosed between 1998 and 26 valid data could be obtained for this item. For a total of 2,229 cases an evaluable classification was established. The accumulated percentage exceeds the % value because patients are potientially considered in more than one subgroup. The grey line represents the subgroup of 67 patients with missing values regarding (2.9 % of 2,296 patients, the percent values of all other categories are related to n=2,229). Due to substantial changes in stage classification schemes long-term survival statistics over decades could not be created. T1 T2 T3+4 N N+ NX M1 n=1,162 n=421 n=614 n=1,186 n=394 n=46 n=114 obs. % rel. % obs. % rel. % obs. % rel. % obs. % rel. % obs. % rel. % obs. % rel. % obs. % rel. %
7 GENERAL ICD- C73: Thyroid cancer Page 7 of 15 cont'd NA/NOS n=67 obs. % rel. % Table 4d. Observed (obs.) and relative (rel.) survival of patients with thyroid cancer by TNM staging for period (N=2,229).
8 GENERAL ICD- C73: Thyroid cancer Page 8 of 15 ICD- C73: Malignant neoplasm of thyroid gland % Relative survival N=3, T1 n=2, % T2 n= % T3+4 n= % N n=1, % N+ n= % NX n=1, % M1 n= % NA/NOS n=7 1.8% Figure 4e. Relative survival of patients with thyroid cancer by. For 3,855 of 3,922 cases diagnosed between 27 and 215 valid data could be obtained for this item. For a total of 3,852 cases an evaluable classification was established. The accumulated percentage exceeds the % value because patients are potientially considered in more than one subgroup. The grey line represents the subgroup of 7 patients with missing values regarding (1.8 % of 3,922 patients, the percent values of all other categories are related to n=3,852). Due to substantial changes in stage classification schemes long-term survival statistics over decades could not be created. T1 T2 T3+4 N N+ NX M1 n=2,461 n=465 n=876 n=1,652 n=689 n=1,147 n=142 obs. % rel. % obs. % rel. % obs. % rel. % obs. % rel. % obs. % rel. % obs. % rel. % obs. % rel. % cont'd NA/NOS n=7 obs. % rel. % Table 4f. Observed (obs.) and relative (rel.) survival of patients with thyroid cancer by for period (N=3,852).
9 GENERAL ICD- C73: Thyroid cancer Page 9 of 15 ICD- C73: Malignant neoplasm of thyroid gland Extent of disease % Conditional relative 5 year survival N=6, Extent of disease Local n=5, % Regional n=1, % Distant n= % 7 NA/NOS n= % Time since diagnosis (years) Figure 4g. Conditional relative 5-year survival of patients with thyroid cancer by extent of disease. For 6,98 of 7,95 cases diagnosed between 1988 and 215 valid data could be obtained for this item. For a total of 6,899 cases an evaluable classification was established. The grey line represents the subgroup of 196 patients with missing values regarding extent of disease (2.8 % of 7,95 patients, the percent values of all other categories are related to n=6,899). Extent of disease Local Regional Distant NA/NOS Cond. Cond. Cond. Cond. surv. % surv. % surv. % surv. % n 5 yrs n 5 yrs n 5 yrs n 5 yrs 5, , , , , , , , , , , , Table 4h. Conditional relative 5-year survival of patients with thyroid cancer by extent of disease for period (N=6,899). Conditional relative survival rates refer to the relative survival probability, in this case for 5 years after cancer diagnosis, compared to the age- and sex-matched population (= %) under the condition of being alive for a certain time period (x-axis in Figure 4e). The results illustrate to what extent the cancer induced mortality of particular subgroups declines in the subsequent years after detection of the malignancy. For instance, according to the presented survival statistics, patients in the subgroup extent of disease= Local, who are alive at least 3 years after cancer diagnosis, the conditional relative 5-year survival rate is.% (n=4,182).
10 PROGRESSION ICD- C73: Thyroid cancer Page of 15 % Time to first progression (TTP) N=5, Type of progression Any type (CI) Events=421 Any type (1-KM) Events=421 Local relapse (CI) Events=87 Local relapse (1-KM) Events=87 Lymph node (CI) Events=135 Lymph node (1-KM) Events=135 Distant metastasis (CI) Events=223 Distant metast. (1-KM) Events=223 NOS (CI) Events=36 NOS (1-KM) Events=36 Figure 5a. Time to first progression of 5,882 patients with thyroid cancer diagnosed between 1998 and 215 (in solid cancers M only) estimated by cumulative incidence function (CI, solid line) accounting for death as competing risk and by inverse Kaplan-Meier estimate (1-KM, dashed line). The frequency of events may be underestimated due to underreporting. Type of progression Distant Any type (CI) Any type (1-KM) Local relapse (CI) Local relapse (1-KM) Lymph node (CI) Lymph node (1-KM) metastasis (CI) n=5,882 n=5,882 n=5,882 n=5,882 n=5,882 n=5,882 n=5,882 % % % % % % %
11 PROGRESSION ICD- C73: Thyroid cancer Page 11 of 15 Type of progression Distant cont'd metast. (1- NOS (CI) NOS (1-KM) KM) n=5,882 n=5,882 n=5,882 % % % Table 5b. Time to first progression of patients with thyroid cancer for period (N=5,882).
12 PROGRESSION ICD- C73: Thyroid cancer Page 12 of 15 ICD- C73: Malignant neoplasm of thyroid gland Progression type % Observed post-progression survival N= Figure 5c. Observed post-progression survival of 567 patients with thyroid cancer diagnosed between 1998 and 215. These 567 patients with documented progression events during their course of disease represent 9.2 % of the totally 6,132 evaluated cases (incl. M1, n=25, 4.1 %). Patients with cancer relapse documented via death certificates only were excluded (n=4, 1.7 %). Multiple progression types on different sites are included in the evaluation even when not occuring synchronously. The NOS (not otherwise specified) class is included under the condition, that it is the one and only progression type during the course of disease. Medical record documentation often lacks the linguistic severity to distinguish between local relapse, regional lymph node metastasis and distant spread in solid cancers. Frequently, the statement not specified is the only information in registries regarding relapse of the disease. The category Any type denotes all cases who suffered from at least one relapse during the course of disease (incl. primary M1-status). Although, the real number of relapsed patients is likely to be much higher. The accumulated percentage of patients with local relapse or distant metastasis exceeds the % value because patients are potientially considered in more than one subgroup. Type of progression Any type Local relapse Lymph node Distant metastasis NOS n=567 n=2 n=15 n=414 n=36 % % % % % Table 5d. Observed post-progression survival of patients with thyroid cancer for period (N=567). Type of progression Any type n=567.% Local relapse n=2 18.% Lymph node n= % Distant metastasis n= % NOS n=36 6.3%
13 PROGRESSION ICD- C73: Thyroid cancer Page 13 of 15 ICD- C73: Malignant neoplasm of thyroid gland Type of Progression: Distant metastasis % Observed post-progression survival by period of progression date N= Figure 5e. Observed post-progression (distant metastasis) survival of 549 patients with thyroid cancer diagnosed between 1988 and 215 by period of progression. Period of progression n=97 n=178 n=274 % % % Table 5f. Observed post-progression (distant metastasis) survival of patients with thyroid cancer for period by period of progression (N=549). Period of progression n= % n= % 27+ n= %
14 USAGE ICD- C73: Thyroid cancer Page 14 of 15 Shortcuts MCR Munich Cancer Registry, Germany NCI National Cancer Institute, USA SEER Surveillance, Epidemiology, and End Results, USA UICC Union for International Cancer Control, Geneva DCO Death certificate only NA Not available NOS Not otherwise specified Death certificate provides the only notification to the registry. OS Overall/Observed survival Overall/Observed survival (Kaplan-Meier estimate) Date of entry: diagnosis Event: death from any cause RS Relative survival Survival compared to general population, ratio of observed to expected survival (Ederer II method), reflecting cancer specific survival AS Assembled survival Assembled chart of observed, expected, relative survival CS Conditional survival Survival probability under the condition of surviving a given period of time TTP Time to progression Time to first progression / relapse Date of entry: diagnosis Event: (progression/ relapse): first local-, lymph node recurrence, distant metastasis or unspecified progression 1-KM CI 1 minus Kaplan-Meier estimator ( inverse Kaplan-Meier estimator) Cumulative incidence Death as competing risk (according to Kalbfleisch und Prentice) PPS Post-progression survival Survival since first progression / relapse (Kaplan-Meier estimate) Date of entry (progression / relapse): first local-, lymph node recurrence, distant metastasis or unspecified progression Event: death from any cause Recommended Citation Munich Cancer Registry. Survival ICD- C73: Thyroid cancer [Internet]. 217 [updated 217 Aug 22; cited 217 Oct 1]. Available from: E-ICD--C73- Thyroid-cancer-survival.pdf Copyright The content of the public web site provided by the Munich Cancer Registry is available worldwide and free of charge. All documents are free to download, utilize, copy, print-out and distribute, providing that the MCR is referenced. Disclaimer The Munich Cancer Registry reserves the right to not be responsible for the topicality, correctness, completeness or quality of the information provided. Liability claims regarding damage caused by the use of any information provided, including any kind of information which is incomplete or incorrect, will therefore be rejected.
15 INDEX ICD- C73: Thyroid cancer Page 15 of 15 Fig./Tbl. Index of figures and tables Page 1a Relative survival by period of diagnosis (chart) 2 1b Survival by period of diagnosis (table) 2 2a Survival by gender (chart) 3 2b Survival by gender (table) 3 3a Relative survival by age category (chart) 4 3b Survival by age category (table) 4 4a Relative survival by histology (chart) 5 4b Survival by histology (table) 5 4c Relative survival by (chart) 6 4d Survival by (table) 6 4e Relative survival by 27+ (chart) 8 4f Survival by 27+ (table) 8 4g Conditional survival by extent of disease (chart) 9 4h Conditional survival by extent of disease (table) 9 5a Time to first progression (chart) 5b Time to first progression (table) 5c Observed post-progression survival (chart) 12 5d Observed post-progression survival (table) 12 5e Observed post-progression survival by period of progression (chart) 13 5f Observed post-progression survival by period of progression (table) 13
GENERAL ICD- C61: Prostate cancer Page 2 of 18 ICD- C61: Malignant neoplasm of prostate Period of diagnosis % Relative survival N=46,
Munich Cancer Registry Incidence and Mortality Selection Matrix Homepage Deutsch ICD- C61: Prostate cancer Survival Year of diagnosis 1988-1997 1998-215 Patients 7,45 49,513 Diseases 7,45 49,514 Cases
More informationMunich Cancer Registry
Munich Cancer Registry Incidence and Mortality Selection Matrix Homepage Deutsch ICD- C1, C5, C9-: Oropharynx cancer Survival Year of diagnosis 1988-1997 1998-16 Patients 821 3,2 Diseases 822 3,291 Cases
More informationMunich Cancer Registry
Munich Cancer Registry Incidence and Mortality Selection Matrix Homepage Deutsch ICD-1 C54: Corpus cancer Survival Year of diagnosis 1988-1997 1998-16 Patients 2,146 9,811 Diseases 2,146 9,811 Cases evaluated
More informationMunich Cancer Registry
Munich Cancer Registry Incidence and Mortality Selection Matrix Homepage Deutsch ICD-1 C69: Eye cancer Survival Year of diagnosis 1988-1997 1998-16 Patients 259 545 Diseases 261 546 Cases evaluated 238
More informationMunich Cancer Registry
Munich Cancer Registry Incidence and Mortality Selection Matrix Homepage Deutsch Survival Year of diagnosis 1988-1997 1998-16 Patients 467 1,895 Diseases 467 1,895 Cases evaluated 452 1,6 Creation date
More informationMunich Cancer Registry
Munich Cancer Registry Incidence and Mortality Selection Matrix Homepage Deutsch ICD-1 C66: Ureteral cancer Survival Year of diagnosis 1988-1997 1998-16 Patients 93 623 Diseases 93 631 Cases evaluated
More informationMunich Cancer Registry
Munich Cancer Registry Incidence and Mortality Selection Matrix Homepage Deutsch Survival Year of diagnosis 1988-1997 1998-16 Patients 64 4 Diseases 64 4 Cases evaluated 489 Creation date 8/22/18 Export
More informationMunich Cancer Registry
Munich Cancer Registry Incidence and Mortality Selection Matrix Homepage Deutsch ICD- C56: Ovarian cancer Survival Year of diagnosis 1988-1997 1998-16 Patients 1,547 7,273 Diseases 1,547 7,275 Cases evaluated
More informationMunich Cancer Registry
Munich Cancer Registry Incidence and Mortality Selection Matrix Homepage Deutsch Survival Year of diagnosis 1988-1997 1998-2016 Patients 52 85 Diseases 52 85 Cases evaluated 50 61 Creation date 08/22/2018
More informationMunich Cancer Registry
Munich Cancer Registry Survival Selection Matrix Homepage Deutsch ICD-10 C46: Kaposi sarcoma Incidence and Mortality Year of diagnosis 1998-2016 Patients 85 Diseases 85 Creation date 08/21/2018 Export
More informationCases with invasive cancer by year of diagnosis, proportions of DCO, further malignancies, deaths, and active follow-up (incl.
Munich Cancer Registry Survival Selection Matrix Homepage Deutsch ICD-10 C57: Female genitale cancer NOS Incidence and Mortality Year of diagnosis 1998-2015 Patients 619 Diseases 619 Creation date 02/01/2018
More informationCases by year of diagnosis, proportions of further malignancies, deaths, and active follow-up (ALL PATIENTS)
Munich Cancer Registry Survival Selection Matrix Homepage Deutsch ICD-10 D32: Meninges neoplasm Incidence and Mortality Year of diagnosis 1998-2015 Patients 2,545 Diseases 2,547 Creation date 02/01/2018
More informationMunich Cancer Registry
Munich Cancer Registry Survival Selection Matrix Homepage Deutsch ICD-10 C69: Eye melanoma Incidence and Mortality Year of diagnosis 1998-2016 Patients 327 Diseases 327 Creation date 08/21/2018 Export
More informationMunich Cancer Registry
Munich Cancer Registry Survival Selection Matrix Homepage Deutsch ICD-10 C61: Prostate cancer Incidence and Mortality Year of diagnosis 1998-2016 Patients 51,786 Diseases 51,786 Creation date 08/21/2018
More informationMunich Cancer Registry
Munich Cancer Registry Survival Selection Matrix Homepage Deutsch ICD-10 C23-C24: Gallbladder cancer Incidence and Mortality Year of diagnosis 1998-2016 Patients 3,996 Diseases 4,002 Creation date 08/21/2018
More informationMunich Cancer Registry
Munich Cancer Registry Survival Selection Matrix Homepage Deutsch ICD-10 C73: Thyroid cancer Incidence and Mortality Year of diagnosis 1998-2016 Patients 7,554 Diseases 7,610 Creation date 08/21/2018 Export
More informationMunich Cancer Registry
Munich Cancer Registry Survival Selection Matrix Homepage Deutsch ICD-10 C15: Oesophagus cancer Incidence and Mortality Year of diagnosis 1998-2016 Patients 4,552 Diseases 4,553 Creation date 08/21/2018
More informationMunich Cancer Registry
Munich Cancer Registry Survival Selection Matrix Homepage Deutsch ICD-10 D03: Melanoma in situ Incidence and Mortality Year of diagnosis 1998-2016 Patients 5,466 Diseases 5,704 Creation date 08/21/2018
More informationMunich Cancer Registry
Munich Cancer Registry Survival Selection Matrix Homepage Deutsch ICD-10 C54: Corpus cancer Incidence and Mortality Year of diagnosis 1998-2016 Patients 9,811 Diseases 9,811 Creation date 08/21/2018 Export
More informationMunich Cancer Registry
Munich Cancer Registry Survival Selection Matrix Homepage Deutsch ICD-10 C88.4: MALT lymphoma Incidence and Mortality Year of diagnosis 1998-2016 Patients 1,041 Diseases 1,046 Creation date 08/21/2018
More informationCases with invasive cancer by year of diagnosis, proportions of DCO, further malignancies, deaths, and active follow-up (ALL PATIENTS) (incl.
Munich Cancer Registry Survival Selection Matrix Homepage Deutsch ICD-10 C07, C08: Salivary gland cancer Incidence and Mortality Year of diagnosis 1998-2015 Patients 758 Diseases 759 Creation date 02/01/2018
More informationMunich Cancer Registry
Munich Cancer Registry Survival Selection Matrix Homepage Deutsch ICD-10 C64: Kidney cancer Incidence and Mortality Year of diagnosis 1998-2016 Patients 11,292 Diseases 11,533 Creation date 08/21/2018
More informationMunich Cancer Registry
Munich Cancer Registry Survival Selection Matrix Homepage Deutsch ICD-10 C70-C72: Brain/nerves cancer Incidence and Mortality Year of diagnosis 1998-2016 Patients 5,904 Diseases 5,912 Creation date 08/21/2018
More informationMunich Cancer Registry
Munich Cancer Registry Survival Selection Matrix Homepage Deutsch ICD-10 C64-C68: Urinary tract cancer Incidence and Mortality Year of diagnosis 1998-2016 Patients 23,443 Diseases 24,423 Creation date
More informationINTRODUCTION TO CANCER STAGING
INTRODUCTION TO CANCER STAGING Patravoot Vatanasapt, MD Dept. Otorhinolaryngology Khon Kaen Cancer Registry Faculty of Medicine Khon Kaen University THAILAND Staging is the attempt to assess the size
More information4/10/2018. SEER EOD and Summary Stage. Overview KCR 2018 SPRING TRAINING. What is SEER EOD? Ambiguous Terminology General Guidelines
SEER EOD and Summary Stage KCR 2018 SPRING TRAINING Overview What is SEER EOD Ambiguous Terminology General Guidelines EOD Primary Tumor EOD Regional Nodes EOD Mets SEER Summary Stage 2018 Site Specific
More informationGet The Cancer Staging Manual Pdf Thyroid
Get The Cancer Staging Manual Pdf Thyroid Most people with thyroid cancer have no known risk factors that they can change, Manual. They are based on the stage of the cancer when the person is first. Staging
More informationBoot Camp /5/15
Abstracting & Coding Boot Camp: Cancer Case Scenarios 2014-2015 NAACCR Webinar Series March 5, 2015 Q&A Please submit all questions concerning webinar content through the Q&A panel. Reminder: If you have
More informationLung Cancer and Mesothelioma Site Specific Clinical Reference Group Data Quality Report 2009
Lung Cancer and Mesothelioma Site Specific Clinical Reference Group Data Quality Report 9 Sharma P Riaz Karen M Linklater Henrik Møller Margreet Lüchtenborg Contents 1. Introduction... 1 2. Methods...
More informationSurgical Management of Metastatic Colon Cancer: analysis of the Surveillance, Epidemiology and End Results (SEER) database
Surgical Management of Metastatic Colon Cancer: analysis of the Surveillance, Epidemiology and End Results (SEER) database Hadi Khan, MD 1, Adam J. Olszewski, MD 2 and Ponnandai S. Somasundar, MD 1 1 Department
More informationOutline. How to Use the AJCC Cancer Staging Manual, 7 th ed. 7/9/2015 FCDS ANNUAL CONFERENCE ST PETERSBURG, FLORIDA JULY 30, 2015.
1 How to Use the AJCC Cancer Staging Manual, 7 th ed. FCDS ANNUAL CONFERENCE ST PETERSBURG, FLORIDA JULY 30, 2015 Steven Peace, CTR Outline 2 History, Purpose and Background Purchase and Ordering Information
More informationThyroid Cancer: When to Treat? MEGAN R. HAYMART, MD
Thyroid Cancer: When to Treat? MEGAN R. HAYMART, MD ASSOCIATE PROFESSOR OF MEDICINE UNIVERSITY OF MICHIGAN MICHIGAN AACE 2018 ANNUAL MEETING Thyroid Cancer: When Not to Treat? FOCUS WILL BE ON LOW-RISK
More informationThe projection of short- and long-term survival for. Conditional Survival Among Patients With Carcinoma of the Lung*
Conditional Survival Among Patients With Carcinoma of the Lung* Ray M. Merrill, PhD, MPH; Donald Earl Henson, MD; and Michael Barnes, PhD Objective: One- and 5-year probabilities of survival or death change
More informationCANCER REPORTING IN CALIFORNIA: ABSTRACTING AND CODING PROCEDURES California Cancer Reporting System Standards, Volume I
CANCER REPORTING IN CALIFORNIA: ABSTRACTING AND CODING PROCEDURES California Cancer Reporting System Standards, Volume I Changes and Clarifications 16 th Edition April 15, 2016 Quick Look- Updates to Volume
More informationChapter 13 Cancer of the Female Breast
Lynn A. Gloeckler Ries and Milton P. Eisner INTRODUCTION This study presents survival analyses for female breast cancer based on 302,763 adult cases from the Surveillance, Epidemiology, and End Results
More informationWHI Extension Appendix A, Form Report of Cancer Outcome (Ver. 8.2) Page 1
WHI Extension Appendix A, Form 130 - Report of Cancer Outcome (Ver. 8.2) Page 1 FORM: 130 - REPORT OF CANCER OUTCOME Version: 8.2 October 30, 2008 Description: When used: Purpose: 4-page form filled out
More informationManagement guideline for patients with differentiated thyroid cancer. Teeraporn Ratanaanekchai ENT, KKU 17 October 2007
Management guideline for patients with differentiated thyroid Teeraporn Ratanaanekchai ENT, KKU 17 October 2007 Incidence (Srinagarind Hospital, 2005, both sex) Site (all) cases % 1. Liver 1178 27 2. Lung
More informationQuality ID #250 (NQF 1853): Radical Prostatectomy Pathology Reporting National Quality Strategy Domain: Effective Clinical Care
Quality ID #250 (NQF 1853): Radical Prostatectomy Pathology Reporting National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Process
More informationEthnic Disparities in the Treatment of Stage I Non-small Cell Lung Cancer. Juan P. Wisnivesky, MD, MPH, Thomas McGinn, MD, MPH, Claudia Henschke, PhD,
Ethnic Disparities in the Treatment of Stage I Non-small Cell Lung Cancer Juan P. Wisnivesky, MD, MPH, Thomas McGinn, MD, MPH, Claudia Henschke, PhD, MD, Paul Hebert, PhD, Michael C. Iannuzzi, MD, and
More informationThyroid Cancer in New Mexico
Thyroid Cancer in New Mexico Time Trends and Surgical Treatment Preferences Ihsan Mahdi MD MPH Introduction The incidence of thyroid cancer incidence is increasing more rapidly than any other malignancy
More informationSubject: Axitinib (Inlyta ) Tablets
09-J1000-67 Original Effective Date: 05/15/12 Reviewed: 12/12/18 Revised: 01/15/19 Subject: Axitinib (Inlyta ) Tablets THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION, EXPLANATION
More informationRecurrent lung cancer icd 10
Search... Recurrent lung cancer icd 10 1-10-2017 2018 ICD - 10 -CM Diagnosis unsp part of unsp bronchus or lung ; The 2018 edition of ICD - 10 -CM C34.90 became due to small cell lung cancer ; Free, official
More informationResearch Article Clinical Features and Outcomes Differ between Skeletal and Extraskeletal Osteosarcoma
Sarcoma, Article ID 902620, 8 pages http://dx.doi.org/10.1155/2014/902620 Research Article Clinical Features and Outcomes Differ between and Osteosarcoma Sheila Thampi, 1 Katherine K. Matthay, 1 W. John
More informationNIFTP: Histopathology of a Cytological Monkey Wrench. B. Wehrli
NIFTP: Histopathology of a Cytological Monkey Wrench B. Wehrli Non-Invasive Encapsulated Follicular Variant of Papillary Thyroid Carcinoma Before 2016 Non-Invasive Follicular Thyroid Neoplasm with Papillary-Like
More informationTrends in Cancer Survival in NSW 1980 to 1996
Trends in Cancer Survival in NSW 19 to 1996 Xue Q Yu Dianne O Connell Bruce Armstrong Robert Gibberd Cancer Epidemiology Research Unit Cancer Research and Registers Division The Cancer Council NSW August
More informationPAPILLARY THYROID CANCER IS A
ORIGINAL ARTICLE Thyroid Cancer Survival in the United States Observational Data From 1973 to 2005 Louise Davies, MD, MS; H. Gilbert Welch, MD, MPH Objective: To compare the survival rate of people with
More informationA Comprehensive Approach to. International Cancer Survival Benchmarking. SurvMark-2
A Comprehensive Approach to International Cancer Survival Benchmarking SurvMark-2 Call for Data Data specification June 2016 The deadline for data submission will be 15 September 2016 and it is essential
More informationBoot Camp /5/15
Abstracting & Coding Boot Camp: Cancer Case Scenarios 2014-2015 NAACCR Webinar Series March 5, 2015 Q&A Please submit all questions concerning webinar content through the Q&A panel. Reminder: If you have
More informationPediatric Thyroid Cancer Lung Metastases. Liora Lazar MD
Pediatric Thyroid Cancer Lung Metastases Liora Lazar MD Differentiated thyroid cancer (DTC) The 3rd most common solid tumor in childhood and adolescence Accounting for 1.5%-3% of all childhood cancers
More informationAbstracting and Coding Boot Camp: Cancer Case Scenarios
NAACC R 2015-2016 Webinar Series Abstracting and Coding Boot Camp: Cancer Case Scenarios NAACCR 2015 2016 Webinar Series Presented by: Angela Martin amartin@naaccr.org Jim Hofferkamp jhofferkamp@naaccr.org
More informationReevaluating the prognostic significance of male gender for papillary thyroid carcinoma and microcarcinoma: a SEER database analysis
www.nature.com/scientificreports Received: 1 May 2017 Accepted: 30 August 2017 Published: xx xx xxxx OPEN Reevaluating the prognostic significance of male gender for papillary thyroid carcinoma and microcarcinoma:
More information3/23/2017. Disclaimer. Common Changes in TNM Staging. Overview. Overview. Understanding Terminology. Overview
Common Changes in TNM Staging Understanding the General Rules of Cancer Staging Thomas P. Baker, MD FCAP March 5, 2017 Disclaimer The identification of specific products or scientific instrumentation is
More informationTrends in the incidence of thyroid cancer, Israel,
Trends in the incidence of thyroid cancer, Israel, 1980-2012 Lital Keinan-Boker, MD, MPH, PhD, Barbara G. Silverman, MD, MPH Israel National Cancer Registry Israel Center for Disease Control Israel Ministry
More informationNorth American Association of Central Cancer Registries, Inc. (NAACCR) What You Need to Know for Version 1.1
North American Association of Central Cancer Registries, Inc. (NAACCR) What You Need to Know for 2017 Version 1.1 January 2017 Revised March 2017 Table of Contents 1 Introduction... 3 2 ICD-O-3 Histologies...
More informationCDC & Florida DOH Attribution
SCCRA/GATRA Regional Conference North Charleston, SC 11/6/2018 Steven Peace, CTR 1 CDC & Florida DOH Attribution Funding for this conference was made possible (in part) by the Centers for Disease Control
More informationEXPLORING THE INTERNAL CONSISTENCY OF REGISTRY DATA ON STAGE OF DISEASE AT DIAGNOSIS
EXPLORING THE INTERNAL CONSISTENCY OF REGISTRY DATA ON STAGE OF DISEASE AT DIAGNOSIS Richard Porter Catherine N. Correa John P. Fulton Holly L. Howe Chris Newton Judy Nowak Steven D. Roffers This paper
More informationAll India Institute of Medical Sciences, New Delhi, INDIA. Department of Pediatric Surgery, Medical Oncology, and Radiology
All India Institute of Medical Sciences, New Delhi, INDIA Department of Pediatric Surgery, Medical Oncology, and Radiology Clear cell sarcoma of the kidney- rare renal neoplasm second most common renal
More informationThyroid INTRODUCTION ANATOMY SUMMARY OF CHANGES
AJC 7/14/06 1:19 PM Page 67 Thyroid C73.9 Thyroid gland SUMMARY OF CHANGES Tumor staging (T) has been revised and the categories redefined. T4 is now divided into T4a and T4b. Nodal staging (N) has been
More informationAJCC TNM 6 th Edition Staging Input Data Dictionary
Catalogue no. 82-225-XIE No. 001 ISSN: 1715-2100 O ISBN: 0-662-41801-8 Manuals AJCC TNM 6 th Edition Staging Input Data Dictionary by Michel Cormier Health Statistics Division Client Custom Services Room
More informationCombined chemotherapy and Radiotherapy for Patients with Breast Cancer and Extensive Nodal Involvement.
Combined chemotherapy and Radiotherapy for Patients with Breast Cancer and Extensive Nodal Involvement. Ung O, Langlands A, Barraclough B, Boyages J. J Clin Oncology 13(2) : 435-443, Feb 1995 STUDY DESIGN
More informationWe re on the Web! Visit us at VOLUME 19 ISSUE 1. January 2015
VOLUME 19 ISSUE 1 January 2015 We re on the Web! Visit us at www.kumc.edu/kcr January is National Cervical Cancer Screening Month. Cervical cancer begins in the lining of the cervix (organ connecting the
More informationCancer in Estonia 2014
Cancer in Estonia 2014 Estonian Cancer Registry (ECR) is a population-based registry that collects data on all cancer cases in Estonia. More information about ECR is available at the webpage of National
More informationRare Neuroendocrine Tumours and Cancers of Endocrine Organs
Rare Neuroendocrine Tumours and Cancers of Endocrine Organs 1. Neuroendocrine Tumours 1.1 General Results Table 1. Neuroendocrine Tumours: Incidence, Trends, Survival Flemish Region 2001-2010 Both Sexes
More informationComparative Analysis of Stage and Other Prognostic Factors Among Urethral, Ureteral, and Renal Pelvis Malignant Tumors
Comparative Analysis of Stage and Other Prognostic Factors Among Urethral, Ureteral, and Renal Pelvis Malignant Tumors Presented to NAACCR Annual Conference 2012 Serban Negoita, MD, DrPH; Marsha Dunn,
More informationNPCR s TNM Stage Calculator
NPCR s TNM Stage Calculator A Tool for Central Registry Quality Control and Consolidation Assistance NAACCR Annual Meeting June 16, 2016 Jennifer Seiffert Northrop Grumman Under contract to NPCR Joseph
More informationCODING STAGE: TNM AND OTHER STAGING SYSTEMS. Liesbet Van Eycken Otto Visser
CODING STAGE: TNM AND OTHER STAGING SYSTEMS Liesbet Van Eycken Otto Visser OVERVIEW PART I Introduction What is stage? Why stage? History and publications of TNM Classification Clinical and pathologic
More informationSummary NAACCR: What you need to know for 2017 Version 1.1. March ICD-O-3 Histologies. Reportability There are no reportability changes in 2017.
Summary NAACCR: What you need to know for 2017 Version 1.1. March 2017 ICD-O-3 Histologies 2.1 New Terms and Codes Not Yet Implemented ICD-O-3 s and terms effective for 2015 was postponed due to CSv2 software
More informationKyle L. Ziegler, CTR. California Cancer Registry U.C. Davis Health System
Kyle L. Ziegler, CTR California Cancer Registry U.C. Davis Health System Overview New Data Items Reportability Clarifications New Coding Rules Grade ICD-O-3 Changes Collaborative Stage v0205 2 New Data
More informationAtlas of cancer incidence and mortality. of the. Association of Population-based Cancer Registries in Germany (GEKID)
Atlas of cancer incidence and mortality of the Association of Population-based Cancer Registries in Germany (GEKID) The interactive cancer atlas of the GEKID Methodological hints Last edit: July 2017 Summary
More informationWHI Extension Section 8 Outcomes Page 8-85
WHI Extension Section 8 Outcomes Page 8-85 8.11 For m 130 Repor t of Cancer Outcome The CCC Outcomes staff places the participant s barcode ID label in the space provided at the top of the form and routes
More informationDx code for breast cancer in remission
Dx code for breast cancer in remission 8-2-2015 This review the first in a series concerning the biology of cancer is a comprehensive survey of oncogenes, tumor-suppressor genes, and microrna. procedure
More informationMeasure #250 (NQF 1853): Radical Prostatectomy Pathology Reporting National Quality Strategy Domain: Effective Clincial Care
Measure #250 (NQF 1853): Radical Prostatectomy Pathology Reporting National Quality Strategy Domain: Effective Clincial Care 2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS, REGISTRY DESCRIPTION: Percentage
More informationNAACCR Webinar Series 1
NAACCR 2009 2010 Webinar Series Collecting Cancer Data: Kidney 1 Questions Please use the Q&A panel to submit your questions Send questions to All Panelist 2 Fabulous Prizes 3 NAACCR 2009 2010 Webinar
More informationExtract from Cancer survival in Europe by country and age: results of EUROCARE-5 a population-based study
EUROCARE-5 on-line database Data and methods Extract from Cancer survival in Europe 1999 2007 by country and age: results of EUROCARE-5 a population-based study De Angelis R, Sant M, Coleman MP, Francisci
More informationUpdate on SLN and Melanoma: DECOG and MSLT-II. Gordon H. Hafner, MD, FACS
Update on SLN and Melanoma: DECOG and MSLT-II Gordon H. Hafner, MD, FACS No disclosures The surgery of malignant disease is not the surgery of organs, it is of the lymphatic system. Lord Moynihan Lymph
More informationTOPIC Presenter Rihab Sidahmed Ibnoaf Arabic perspective of principles of Screening and diagnostics in Ovarian Cancer, Sudan.
Arabic perspective of principles of Screening and diagnostics in Ovarian Cancer, Sudan. Ovarian cancer is the seventh most common cancer, and it is the most common cause of mortality from gynecological
More informationAn Overview of Survival Statistics in SEER*Stat
An Overview of Survival Statistics in SEER*Stat National Cancer Institute SEER Program SEER s mission is to provide information on cancer statistics in an effort to reduce the burden of cancer among the
More informationCERVIX MEASURE SPECIFICATIONS
Cancer Programs Practice Profile Reports (CP 3 R) CERVIX MEASURE SPECIFICATIONS Introduction The Commission on Cancer s (CoC) National Cancer Data Base (NCDB) staff has undertaken an effort to improve
More informationCANCER FACTS & FIGURES For African Americans
CANCER FACTS & FIGURES For African Americans Pennsylvania, 2006 Pennsylvania Cancer Registry Bureau of Health Statistics and Research Contents Data Hightlights...1 Pennsylvania and U.S. Comparison...5
More informationNUMERATOR: Reports that include the pt category, the pn category and the histologic grade
Quality ID #100 (NQF 0392): Colorectal Cancer Resection Pathology Reporting: pt Category (Primary Tumor) and pn Category (Regional Lymph Nodes) with Histologic Grade National Quality Strategy Domain: Effective
More informationTesticular Malignancies /8/15
Collecting Cancer Data: Testis 2014-2015 NAACCR Webinar Series January 8, 2015 Q&A Please submit all questions concerning webinar content through the Q&A panel. Reminder: If you have participants watching
More information2018 IMPLEMENTATION UPDATE: WHAT S NEW IN STAGING FOR 2018?
2018 IMPLEMENTATION UPDATE: WHAT S NEW IN STAGING FOR 2018? SESSION 2 10/20/17 Q&A Please submit all questions concerning webinar content through the Q&A panel. A recording of today s session, the Q&A,
More informationClinically Significant Prognostic Factors for Differentiated Thyroid Carcinoma
524 Clinically Significant Prognostic Factors for Differentiated Thyroid Carcinoma A Population-Based, Nested Case Control Study Catharina Ihre Lundgren, M.D. 1,2 Per Hall, M.D., Ph.D. 1 Paul W. Dickman,
More informationRCC in Adolescents and Young Adults (AYAs): Diagnosis and Management
RCC in Adolescents and Young Adults (AYAs): Diagnosis and Management Nicholas G. Cost, M.D. Assistant Professor, Department of Surgery, Division of Urology University of Colorado Cancer Center Fifteenth
More informationJ Clin Oncol 26: by American Society of Clinical Oncology INTRODUCTION
VOLUME 26 NUMBER 18 JUNE 2 28 JOURNAL OF CLINICAL ONCOLOGY R E V I E W A R T I C L E One Hundred Years After Carcinoid : Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases
More informationSupplementary Online Content
Supplementary Online Content Henson KE, Brock R, Charnock J, Wickramasinghe B, Will O, Pitman A. Risk of suicide after cancer diagnosis in England. JAMA Psychiatry. Published online November 21, 2018.
More informationReport on Cancer Statistics in Alberta. Childhood Cancer
Report on Cancer Statistics in Alberta Childhood Cancer November 2009 Surveillance - Cancer Bureau Health Promotion, Disease and Injury Prevention Report on Cancer Statistics in Alberta - 2 Purpose of
More informationI.2 CNExT This section was software specific and deleted in 2008.
CANCER REPORTING IN CALIFORNIA: ABSTRACTING AND CODING PROCEDURES FOR HOSPITALS California Cancer Reporting System Standards, Volume I Changes and Clarifications 8th th Edition Revised May 2008 SECTION
More informationTopics: Staging and treatment for pancreatic cancer. Staging systems for pancreatic cancer: Differences between the Japanese and UICC systems
M. J Hep Kobari Bil Pancr and S. Surg Matsuno: (1998) Staging 5:121 127 system for pancreatic cancer 121 Topics: Staging and treatment for pancreatic cancer Staging systems for pancreatic cancer: Differences
More informationReport on Cancer Statistics in Alberta. Kidney Cancer
Report on Cancer Statistics in Alberta Kidney Cancer November 29 Surveillance - Cancer Bureau Health Promotion, Disease and Injury Prevention Report on Cancer Statistics in Alberta - 2 Purpose of the Report
More informationCarcinoma of thyroid - clinical presentation and outcome
Med. J. Malaysia Vol. 46 No. 3 September 1991 Carcinoma of thyroid - clinical presentation and outcome K. Sothy, MBBS M. Mafauzy, MBBS, MRCP, M.Med. Sci. W.B. Wan Mohamad, MD, MRCP B.E. Mustaffa, MBBS,
More informationLong-term Follow-up for Patients with Papillary Thyroid Carcinoma Treated as Benign Nodules
Long-term Follow-up for Patients with Papillary Thyroid Carcinoma Treated as Benign Nodules YASUHIRO ITO, TAKUYA HIGASHIYAMA, YUUKI TAKAMURA, AKIHIRO MIYA, KAORU KOBAYASHI, FUMIO MATSUZUKA, KANJI KUMA
More informationCancer registry. Azin.Nahvijou, MD, PhD Candidate
Cancer registry Azin.Nahvijou, MD, PhD Candidate 1 History of Cancer registration: The first efforts to estimate the number of new and existing cases of cancer in a given population were made at the turn
More informationXiang Hu*, Liang Cao*, Yi Yu. Introduction
Original Article Prognostic prediction in gastric cancer patients without serosal invasion: comparative study between UICC 7 th edition and JCGS 13 th edition N-classification systems Xiang Hu*, Liang
More informationNAACCR Hospital Registry Webinar Series
NAACCR Hospital Registry Webinar Series Shannon Vann, CTR Jim Hofferkamp, CTR Webinar Series 1 Abstracting Thyroid Cancer Incidence & Image source: Thyroid ABC Health and Well Being Webinar Series 2 Anatomy
More informationReport on Cancer Statistics in Alberta. Melanoma of the Skin
Report on Cancer Statistics in Alberta Melanoma of the Skin November 29 Surveillance - Cancer Bureau Health Promotion, Disease and Injury Prevention Report on Cancer Statistics in Alberta - 2 Purpose of
More informationNeoplasms/Lymphoma/Leukemia
Neoplasms/Lymphoma/Leukemia Session Guidelines This is a 15 minute webinar session for CNC physicians and staff CNC holds webinars monthly to address topics related to risk adjustment documentation and
More informationInsights into Thymic Epithelial Tumors: Radiation Therapy
Insights into Thymic Epithelial Tumors: Radiation Therapy Charles R. Thomas, MD Professor and Chairman, Department of Radiation Medicine Professor, Department of Medicine, Division of Hematology/Medical
More informationValidation of the T descriptor in the new 8th TNM classification for non-small cell lung cancer
Original Article Validation of the T descriptor in the new 8th TNM classification for non-small cell lung cancer Hee Suk Jung 1, Jin Gu Lee 2, Chang Young Lee 2, Dae Joon Kim 2, Kyung Young Chung 2 1 Department
More informationSEER EOD AND SUMMARY STAGE ABSTRACTORS TRAINING
SEER EOD AND SUMMARY STAGE ABSTRACTORS TRAINING OVERVIEW What is SEER EOD Ambiguous Terminology General Guidelines EOD Primary Tumor EOD Regional Nodes EOD Mets Site Specific Data Items (SSDI) SEER Summary
More information